Functional Dyspepsia Drug Market

Functional dyspepsia, also known as non-ulcer dyspepsia or indigestion, is a term used to describe a group of symptoms affecting the gastrointestinal tract, including stomach pain or discomfort, nausea, bloating and belching. The condition is diagnosed when no obvious cause can be found for the symptoms present, though a small percentage of cases are caused by infection with the germ Helicobacter pylori.

Functional Dyspepsia Drug Market contains market size and forecasts of Functional Dyspepsia Drug in global, including the following market information:

Global Functional Dyspepsia Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Functional Dyspepsia Drug Market Sales, 2017-2022, 2023-2028, (M Units)

Global top five Functional Dyspepsia Drug companies in 2021 (%)

The global Functional Dyspepsia Drug market was valued at 6121.1 million in 2021 and is projected to reach US$ 7365.8 million by 2028, at a CAGR of 2.7% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Prokinetic Drugs Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Functional Dyspepsia Drug include Bayer, Sumitomo, Cadila Pharmaceuticals, Teva, Johnson & Johnson, Pfizer, Sanofi, AstraZeneca and Jiangsu Aosaikang Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Functional Dyspepsia Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Functional Dyspepsia Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Functional Dyspepsia Drug Market Segment Percentages, by Type, 2021 (%)

• Prokinetic Drugs
• Gastric Antisecretory Drugs
• Others

Global Functional Dyspepsia Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Functional Dyspepsia Drug Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Drugstores

Global Functional Dyspepsia Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (M Units)

Global Functional Dyspepsia Drug Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Functional Dyspepsia Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Functional Dyspepsia Drug revenues share in global market, 2021 (%)
• Key companies Functional Dyspepsia Drug sales in global market, 2017-2022 (Estimated), (M Units)
• Key companies Functional Dyspepsia Drug sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Bayer
• Sumitomo
• Cadila Pharmaceuticals
• Teva
• Johnson & Johnson
• Pfizer
• Sanofi
• AstraZeneca
• Jiangsu Aosaikang Pharma
• Eisai
• Kyowa Kirin Pharmaceuticals
• Hanmi Pharm